Motilal Oswal has maintained a positive outlook on Ellenbarrie Industrial Gases, setting a price target of Rs 420. The brokerage points to rising demand from India's pharmaceutical and solar manufacturing sectors as key drivers. Analysts project a 40% revenue growth rate for the company through 2029, fueled by planned capacity additions in Northern and Central India.
Motilal Oswal Financial Services has reaffirmed its positive stance on Ellenbarrie Industrial Gases. The brokerage firm set a price target of Rs 420 per share, citing a strong growth outlook for the company based on its positioning in key industrial sectors. This update comes as the company focuses on expanding its footprint in Northern and Central India to meet the growing need for industrial gases.
Growth Drivers and Business Model
The brokerage anticipates that the company will benefit significantly as India expands its role as a manufacturing center for pharmaceuticals and solar products. Industrial gases are essential for these processes, and the move by many companies to shift supply chains away from China is expected to boost local demand.
Ellenbarrie’s business model is built on long-term contracts, which provide predictable revenue. According to recent data, bulk supplies make up the majority of its revenue at 68%, while packaged and onsite supplies account for 15% and 16%, respectively. This structure helps in maintaining consistent customer relationships and stable income. The company is now actively trying to widen its client base by targeting the domestic solar cell manufacturing ecosystem, a sector that requires specialized gas supplies.
Financial Outlook and Risks
Analysts project that the company could see a revenue growth rate of 40% annually through fiscal year 2029. While this outlook appears positive, investors should consider the challenges inherent in the industrial gas business. The production of industrial gases is energy-intensive, meaning profit margins may come under pressure if electricity or raw material costs rise sharply.
Furthermore, the company is planning significant capital spending to expand its capacity. While this is intended to support future growth, it also increases the use of borrowings. Investors should watch the company’s ability to manage its debt levels while funding these large projects. There is also the risk of delay or cost increases in setting up new plants, which could impact the timeline for when these projects start contributing to profits.
What Investors Should Monitor
The performance of the company will largely depend on how effectively it executes its expansion plans and manages costs in a competitive environment. The primary monitorable for shareholders will be the commissioning status of the new plants in North and Central India and how quickly these facilities reach full production. Additionally, any changes in demand from the steel and pharmaceutical sectors—which are cyclical by nature—will be important for investors to track, as these sectors significantly influence the company's overall revenue performance.